Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluates pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for early-stage ER+/HER2- breast cancer; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING